The Witchita CCOP is a consortium of three hospitals with a total of 2,246 beds. The medical community has an already organized cancer program through the Wichita Community Hospital Oncology Program (WCHOP). The administrative structure and space for a CCOP are, therefore, already in existence.
The specific aims of the Wichita CCOP are: 1) to bring the benefits that result from participation in clinical trials to cancer patients in Wichita and its surrounding catchment area of southern Kansas and northern Oklahoma - a patient population which would otherwise be unserved because its geographic location is remote from comprehensive cancer centers; 2) to increase accrual of patients on high priority protocols and thus reduce the time necessary to answer critical questions; 3) to strengthen and broaden the Wichita cancer program which is already one of the 17 NCI funded CHOP programs as a resource for future cancer control and prevention research activities of the NCI. We plan to enter a minimum of 150 patients yearly on protocols using three research bases, Southwest Oncology Group (100 patients), Comprehensive Cancer Center of Metropolitan Detroit (25 patients) and Pediatric Oncology Group (25 patients). With over 2,000 new cancer patients each year and 13 years experience by Wichita CCOP physicians participating in the research activities of these same three research bases, we have the necessary number of patients, experience, expertise and commitment to establish a successful CCOP. We are combining the CHOP and CCOP into one administrative organization which should increase the chance of success of both programs as well as provide a more comprehensive base for participation in future NCI cancer control activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035431-03S1
Application #
3557771
Study Section
(SRC)
Project Start
1983-09-15
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
St. Francis Regional Medical Center
Department
Type
DUNS #
City
Wichita
State
KS
Country
United States
Zip Code
67214
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8

Showing the most recent 10 out of 307 publications